Comparative study on the efficacy of lomefloxacin (NY-198) and cefaclor in respiratory tract infections

Kaoru Shimada, Yasuyuki Sano, Yasufumi Miyamoto, Akira Saito, Masumi Tomizawa, Ichiro Nakayama, Osamu Yajima, Yohmei Hiraga, Mitsuhide Ohmichi, Kazuo Takebe, Toyokazu Tamura, Katsumi Endoh, Tamotsu Takishimam, Shiroh Ida, Kiyoshi Konno, Kohtaro Ohizumi, Seiichi Aonuma, Akira Watanabe, Kohsaku Nagai, Kazuo SatohIzumi Hayashi, Kikuo Ohnuma, Masataka Katsu, Takeo Toyoda, Toshio Fukui, Kohji Ogihara, Tadashi Miyahara, Atsushi Saito, Jingoro Shimada, Kohya Shiba, Hiroichi Tanimoto, Koichiro Nakata, Tatsuo Nakatani, Takashi Inamatsu, Makiko Fukayama, Hiroyuki Kobayashi, Shin Kawai, Tatsuo Katoh, Masaru Koyama, Kentaro Watanabe, Otohiko Kunii, Hajime Nishiya, Kazufuto Fukaya, Takao Okubo, Akira Ito, Ippei Fujimori, Yoshio Kobayashi, Mitsuo Obana, Kazuhiko Someya, Satoru Takahashi, Satoru Naito, Yoshiaki Nagayama, Fumio Matsumoto, Shigeki Odagiri, Kaneo Suzuki, Kou Murohashi, Masaaki Arakawa, Koichi Wada, Akio Hoshino, Osamu Sekine, Nobuki Aoki, Kaoru Oyama, Nobuo Ohya, Mitsuru Hayase, Toshiyuki Yamamoto, Kanzo Suzuki, Kazuhide Yamamoto, Satoru Adachi, Shigeru Shirakawa, Nobuyuki Minami, Naoyuki Katayama, Kojiro Yasunaga, Seibun Yonezu, Kenzo Shiota, Keiji Kobayashi, Makoto Ohashi, Fumio Miki, Eiro Tsubura, Masaru Nakagawa, Rinzo Soejima, Yoshihito Niki, Yoshihisa Nakagawa, Toshiharu Matsushima, Michio Yamakido, Shinichi Ishioka, Osamu Kurimura, Hideo Sasaki, Hirofumi Fukuhara, Yoshiro Sawae, Yukio Kumagai, Koji Takaki, Hitoshi Nagano, Chiharu Kubo, Kohji Honda, Hozumi Yamada, Osamu Katoh, Atsushi Shinoda, Tsuneo Ishibashi, Masahiro Takamoto, Kohei Hara, Masaki Hirota, Keizo Yamaguchi, Shigeru Kohno, Yasumasa Doutsu, Akira Yasuoka, Kazuo Sasayama, Toshiaki Hayashi, Kohta Kohno, Masao Nakatomi, Keizo Matsumoto, Tsuyoshi Nagatake, Harumi Shishido, Masaru Nasu, Jun Goto, Hideaki Shigeno, Takayoshi Tashiro, Shukuro Araki, Masayuki Ando, Moritaka Suga, Haruhiko Tokuomi, Yasutsugu Fukuda, Katsumasa Tokunaga, Mitsuyoshi Nakashima

    Research output: Contribution to journalArticlepeer-review

    4 Citations (Scopus)

    Abstract

    To evaluate the efficacy, safety and usefulness of lomefloxacin (NY-198), a new synthetic quinolone antimicrobial agent, in respiratory tract infections (bacterial pneumonia and chronic respiratory infections), we carried out a double-blind comparative study with cefaclor (CCL) as a reference drug. NY-198 at daily doses of 600 mg (3 divided doses) and 1, 500 mg of CCL (3 divided doses) were orally administered for 14 days, and the following results were obtained: 1) Of a total of 358 patients (180 in the NY-198 group and 178 in the CCL group), 290 (146 in the NY-198 group and 144 in the CCL group) were assigned by the committee for the evaluation of efficacy, 333 (167 and 166, respectively) for evaluation of side effects, 305 (156 and 149, respectively) for evaluation of abnormal changes in laboratory findings and 298 (152 and 146, respectively) for evaluation of usefulness. There were no significant differences between the two groups with respect to the rate of exclusions and dropouts or background factors of patients. 2) The efficacy rate determined by the committee was 73.3% in the NY-198 group and 70.8% in the CCL group with no significant difference between the two groups. As for the bacteriological effiect, the elimination rate of organisms was 78.3%(54/69 isolates) in the NY-198 group and 61.8%(42/58 isolates) in the CCL group, with a significant difference (p=0.041). 3) There were no significant differences between the two groups with respect to the degree of improvement in various symptoms, signs and laboratory findings. 4) Side effects were observed in 12 patients (7.2%) of the NY-198 group and 10 (6.0%) of the CCL group, and abnormal changes in laboratory findings in 21 patients (13.5%) of the NY-198 group and 23 (15.4%) of the CCL group, with no significant difference in incidence. 5) The utility rate (satisfaction rate) calculated by the committee was 68.4% in the NY-198 group and 67.1% in the CCL group, with no significant difference between the two groups. The above results indicate that NY-198 in daily doses of 600 mg is as useful as CCL in daily doses of 1, 500 mg. Especially against Gram-negative bacteria, NY-198 has a higher elimination rate than CCL in the treatment of respiratory tract infections (pneumonia and chronic respiratory infection).

    Original languageEnglish
    Pages (from-to)616-645
    Number of pages30
    JournalChemotherapy
    Volume37
    Issue number5
    DOIs
    Publication statusPublished - 1989

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    Fingerprint Dive into the research topics of 'Comparative study on the efficacy of lomefloxacin (NY-198) and cefaclor in respiratory tract infections'. Together they form a unique fingerprint.

    Cite this